Carl Zeiss to help 100,000 persons with nearsightedness in rural Karnataka
The Hindu
According to the last survey by National Family Health in 2021, 37% of Karnataka’s population was affected by some form of vision health issue.
Carl Zeiss AG, a German manufacturer of optical systems, optical technology and optoelectronics, has partnered with Karnataka government to collaborate with startups to research and develop quality vision-care solutions, devices and therapies for over 1,00,000 myopia (nearsightedness) affected school-going children and adults in rural Karnataka.
“Zeiss India will collaborate with the Karnataka government to make quality vision-care more accessible across Karnataka’s rural and underserved regions,” said Priyank Kharge, Minister of Electronics, IT & BT (Information Technology and Biotechnology), Rural Development and Panchayat Raj.
‘’In addition to a joint Research and Development (R&D) Programme, through the Aloka Vision Programme of Zeiss, this partnership will aim to provide affordable eye-care services to 100,000 individuals over the next three years,” the Minister said.
Addressing the media at the inaugural of Carl Zeiss’ maiden Global Capability Centre (GCC) in India in Bengaluru, Mr. Kharge said, “India now hosts over 4,000 Global Capability Centers (GCCs), with Karnataka alone accounting for 38% of these.”
“In addition to healthcare, the State has the potential to drive growth across diverse sectors, including agritech, aerospace, and technology. ‘I am excited to see the positive outcomes of public-private partnerships. I encourage more such alliances to drive impactful solutions,” he added.
Dhaval Radia, Chief Financial Officer, Carl Zeiss in India, said, “Zeiss’ GCC is a strategic hub that would tap into Bengaluru’s deep IT talent pool to drive technology solutions and further expand the company’s global R&D capabilities. The 43,000 sq. ft facility currently accommodates over 600 engineers with deep domain expertise in the field of vision care technologies.”
According to the last survey by National Family Health in 2021, 37% of Karnataka’s population was affected by some form of vision health issue.
Equity markets decline on weak earnings, global trends; inflation hits 14-month high, foreign funds exit, oil prices rise.
Swiggy IPO debuts with a 7.69% jump at NSE, market valuation at ₹89,549.08 crore; shares listed at ₹412 on BSE.
Shares in Samsung Electronics fell on Wednesday to their lowest level in more than four years.
Mercedes-Benz India introduces the new Mercedes-AMG C 63 S E Performance sportscar with hybrid powertrain and innovative business model.
Hyundai Motor India Ltd. reports 16% profit decline in Q3 due to market sentiments, geopolitical factors, and Red Sea crisis.
Equity market plunges over 800 points, eroding market capitalisation by ₹5.29 lakh crore amid global economic concerns.
Aurobindo Pharma's CuraTeQ Biologics receives EMA GMP certificate for biosimilars, paving way for European approvals of three products.
BCCI to withdraw insolvency plea against Byju's after Supreme Court sets aside NCLAT judgement, NCLT hearing scheduled.
Natco Pharma's Q2 profits soar 83% to ₹676.5 crore, driven by robust exports and stable domestic business.
India's industrial output rebounds with 3.1% growth in September, led by manufacturing, despite weak electricity and mining sectors.
India's retail inflation hits 6.2% in October, driven by a 10.9% spike in food prices, breaching RBI's upper limit.